Insulet Corporation Slides on Report of Increased Adverse Events, Customer Complaints

Published: Sep 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Investors pressure Insulet shares after a report surfaces claiming increased adverse event reports in an FDA database and rampant customer complaints. Insulet (NSDQ:PODD) shares are off some 4.5% since the end of last week, after a JMP Securities report of increase adverse event reports and rampant customer complaints for its OmniPod insulin management device. PODD shares were trading at $37.75 apiece at market's close Sept. 19, having reached a 52-week high, but fell some 5.5% the next day, to $35.69 each after JMP analysts downgraded their rating on Insulet stock to "market perform" from "market outperform."

Help employers find you! Check out all the jobs and post your resume.

Back to news